The company is subject to a number of risks that could materially adversely affect its business, results of operations, cash flow, financial condition, or prospects. The company faces intense competition from both lower-cost generic products and competitors' products, which could impact its ability to maintain operational flexibility and adaptability in a turbulent market environment. The company's significant global operations expose it to additional risks, including changes in medical reimbursement policies, trade protection measures, and foreign exchange fluctuations. Adverse events, such as natural disasters or geopolitical instability, could disrupt operations and negatively affect the company's performance. The company believes climate change poses potential risks to its business, including physical risks from extreme weather events and regulatory risks associated with transitioning to a low-carbon economy. The company is increasingly dependent on sophisticated software applications and computing infrastructure, which makes it vulnerable to cyber-attacks that could disrupt operations. The company’s success is dependent on the successful development and marketing of new products, which are subject to substantial risks, including the potential for unexpected safety or efficacy concerns that could lead to product recalls or declining sales. The company must maintain a continuous flow of successful new products to cover substantial research and development costs and replace sales lost from products losing patent protection. The company has experienced difficulties in manufacturing certain products, which could affect its ability to respond effectively to customer needs and maintain operational continuity. The company’s ability to generate profits largely depends on the continued profitability of key products, and any adverse events affecting these products could have a significant impact on results of operations. The company is actively pursuing strategic initiatives and collaborations to enhance its research and development capabilities and ensure future growth. The company recognizes the importance of attracting and retaining highly qualified personnel to successfully develop and commercialize products. The company faces pressures from evolving environmental, social, and governance (ESG) matters that could impact its reputation and ability to compete. The company is committed to improving its ESG performance, which involves risks and uncertainties that require investments and depend on third-party performance. The company’s capital allocation strategy prioritizes investments in its business to drive near- and long-term growth, including addressing important unmet medical needs. The company anticipates that changes in the healthcare system and increased purchasing power of entities negotiating on behalf of beneficiaries could result in further pricing pressures. The company’s financial profile enables it to fund research and development, finance acquisitions, and support in-line products while providing significant cash returns to shareholders. The company believes its sources of financing will be adequate to meet future requirements, and it actively manages foreign currency and interest rate risks to mitigate potential adverse impacts on earnings and cash flows. The company’s organizational practices and strategic management are focused on maintaining resilience in the face of external pressures and ensuring operational effectiveness amid complex situations.